NYSE - Nasdaq Real Time Price USD

Pfizer Inc. (PFE)

Compare

25.65

+0.52

(+2.07%)

At close: November 22 at 4:00 PM EST

25.60

-0.05

(-0.19%)

After hours: 7:59 PM EST

RFK Jr. Spooks Weight-Loss Stocks. Should Eli Lilly, Novo Nordisk Be Worried?

Robert F. Kennedy Jr.'s potential appointment to HHS has spooked Eli Lilly stock and stocks tied to popular weight-loss drugs.

Investor's Business Daily 12 hours ago

LLY

NONOF

NVO
Pharma Stock Roundup: EU Nod for PFE's Hympavzi, NVS Ups Sales View

EU approval for PFE's hemophilia drug Hympavzi. Novartis upgrades its mid-term sales guidance.

Zacks 13 hours ago

AZN

PFE
+2.07%
NVS
BridgeBio heart drug approved by FDA, setting up battle with Pfizer

The approval of Attruby for transthyretin amyloidosis with cardiomyopathy begins a battle for control of a lucrative market that investors have been skeptical BridgeBio can win.

BioPharma Dive 14 hours ago

BBIO

PFE
+2.07%
ALNY
Novartis Raises Sales Outlook for Mid-Term, Acquires Kate Therapeutics

NVS expects sales to witness a CAGR of 6% during 2023-2028, up from the earlier projection of 5%. The company acquires Kate Therapeutics to strengthen its portflio of gene therapies.

Zacks 14 hours ago

NVS

PFE
+2.07%
FDA Accepts Bayer's Application for Label Expansion of Nubeqa

Bayer's efforts to expand Nubeqa's label in prostate cancer make progress with the FDA's acceptance of the company's sNDA.

Zacks 14 hours ago

BAYN.DE

PFE
+2.07%
Replimune Stock Rallies on BLA Filing for Melanoma Combo Drug

REPL stock soars after submitting a BLA to the FDA seeking accelerated approval for its lead candidate, RP1, in combination with Opdivo for advanced melanoma.

Zacks 17 hours ago

REPL

PFE
+2.07%
Zai Lab and Pfizer to commercialise XACDURO in China

Pfizer's affiliated companies have exclusive rights to undertake commercialisation activities for the drug.

Pharmaceutical Technology 21 hours ago

PFE
+2.07%
ZLAB
The Irish Government Is Unbelievably Rich. It’s Largely Thanks to Uncle Sam.

EUROPE NEWS DUBLIN—The Irish government is rolling in clover like never before. The country currently has so much money it pumps cash into not one but two sovereign-wealth funds. It is so flush that the budget watchdog doesn’t warn about not having enough money but rather that the government is spending so much that it could overheat the economy.

The Wall Street Journal yesterday

GOOG

MSFT

PFE
+2.07%
Novavax Cut Its Outlook Despite Beating Third-Quarter Forecasts. Is It A Sell?

Things were looking up for Novavax stock after the FDA resolved a clinical hold. But the company trimmed its outlook. Is NVAX stock a sell?

Investor's Business Daily yesterday

NVAX

SNY

PFE
+2.07%
PFE vs. NVO: Which Stock Is the Better Value Option?

PFE vs. NVO: Which Stock Is the Better Value Option?

Zacks yesterday

NVO

PFE
+2.07%
Major companies that are also popular short-selling stocks

Investor confidence in certain major companies has propelled markets higher, but there are also those betting against big-name stocks through short selling.

Yahoo Finance UK yesterday

ADANIENT.NS

NVDA

BMY
+1.10%
5 Best Value Stocks With Discounted PEG to Boost Your Portfolio Return

Here are the five PEG-driven value stocks that fit our screening criteria - INGR, PFE, LDOS, LTM and BABA.

Zacks yesterday

PFE
+2.07%
BABA

LDOS
The Zacks Analyst Blog Highlights Adobe, Pfizer, Dollar General, Snap and Ryanair

Adobe, Pfizer, Dollar General, Snap and Ryanair are included in this Analyst Blog.

Zacks yesterday

ADBE

SNAP

DG
Is Pfizer Stock A Sell With Vaccine Skeptic Robert F. Kennedy Jr. Tapped To Lead HHS?

Is Pfizer stock a sell after shares skidded on the news Trump selected Kennedy to take over HHS? Is PFE stock now a sell?

Investor's Business Daily yesterday

PFE
+2.07%
Pfizer Secures Approval for Hemophilia Drug Hympavzi in the EU

Following approval from the European Commission, PFE's Hympavzi becomes the first hemophilia medicine in the European Union to be administered via a pre-filled, auto-injector pen.

Zacks yesterday

PFE
+2.07%
NVO
2 Beaten-Down Healthcare Stocks to Buy Hand Over Fist

For those looking for great candidates, here are two in the healthcare sector: Merck (NYSE: MRK) and Pfizer (NYSE: PFE). Is Merck's Keytruda empire crumbling? The company's famous cancer drug is by far its biggest growth driver and typically accounts for over 40% of its revenue.

Motley Fool yesterday

PFE
+2.07%
EC marketing authorisation granted to Pfizer’s HYMPAVZI for haemophilia

The authorisation extends to all 27 EU member states, along with Liechtenstein, Iceland and Norway.

Pharmaceutical Technology yesterday

PFE
+2.07%
2 Dividend Stocks That Pay More Than 6% That Retirees Can Safely Buy and Hold for Years

High-yielding stocks can be due for cuts to their payouts if a company's underlying financials aren't strong enough to support its dividend payments. Two good examples of stocks that pay more than 6% and can still be ideal long-term options for retirees are Pfizer (NYSE: PFE) and Verizon Communications (NYSE: VZ). A bearish outlook for the future has resulted in Pfizer's stock price tumbling more than 10% this year, despite what has generally been a strong year for the markets.

Motley Fool 2 days ago

PFE
+2.07%
VZ
+1.53%
5 Year-to-Date Laggards to Buy Amid Solid Near-Term Upside Potential

These five laggards of this year have double-digit upside left for the rest of 2024. These are: ADBE, PFE, DG, SNAP, RYAAY.

Zacks 2 days ago

ADBE

SNAP

DG
Pfizer Appoints Cancer Research Head Chris Boshoff as New R&D Chief

Pfizer Names Chris Boshoff as R&D Chief Amid Strategic Focus on Innovation

GuruFocus.com 2 days ago

PFE
+2.07%

Performance Overview

Return	PFE	S&P 500
YTD	-5.46%	+25.15%
1-Year	-10.17%	+31.54%
3-Year	-42.17%	+27.06%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Pfizer Inc. (PFE)

RFK Jr. Spooks Weight-Loss Stocks. Should Eli Lilly, Novo Nordisk Be Worried?

Pharma Stock Roundup: EU Nod for PFE's Hympavzi, NVS Ups Sales View

BridgeBio heart drug approved by FDA, setting up battle with Pfizer

Novartis Raises Sales Outlook for Mid-Term, Acquires Kate Therapeutics

FDA Accepts Bayer's Application for Label Expansion of Nubeqa

Replimune Stock Rallies on BLA Filing for Melanoma Combo Drug

Zai Lab and Pfizer to commercialise XACDURO in China

The Irish Government Is Unbelievably Rich. It’s Largely Thanks to Uncle Sam.

Novavax Cut Its Outlook Despite Beating Third-Quarter Forecasts. Is It A Sell?

PFE vs. NVO: Which Stock Is the Better Value Option?

Major companies that are also popular short-selling stocks

5 Best Value Stocks With Discounted PEG to Boost Your Portfolio Return

The Zacks Analyst Blog Highlights Adobe, Pfizer, Dollar General, Snap and Ryanair

Is Pfizer Stock A Sell With Vaccine Skeptic Robert F. Kennedy Jr. Tapped To Lead HHS?

Pfizer Secures Approval for Hemophilia Drug Hympavzi in the EU

2 Beaten-Down Healthcare Stocks to Buy Hand Over Fist

EC marketing authorisation granted to Pfizer’s HYMPAVZI for haemophilia

2 Dividend Stocks That Pay More Than 6% That Retirees Can Safely Buy and Hold for Years

5 Year-to-Date Laggards to Buy Amid Solid Near-Term Upside Potential

Pfizer Appoints Cancer Research Head Chris Boshoff as New R&D Chief

Performance Overview